Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-10-10 Governance Information
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
承诺管理制度
Governance Information Classification · 95% confidence The document is a formal announcement from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding the approval and content of a 'Commitment Management System' by the company's board of directors. It details the system's purpose, scope, and procedures related to commitments made by the company and related parties. The document includes legal references and procedural rules but does not contain financial statements, earnings data, or other typical financial report content. It is not a report itself but an announcement of a governance-related policy or system. Given the content focuses on company governance and internal rules, it fits best under Governance Information (CGR). The document length is short (2197 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is Governance Information (CGR) with high confidence.
2023-10-10 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions of Jiangxi Xinganjiang Pharmaceutical Co., Ltd., detailing the principles, definitions, decision-making procedures, and responsibilities related to related party transactions. It includes detailed governance and procedural rules but does not contain financial statements, audit results, or earnings data. It is a regulatory disclosure about internal governance and compliance with related party transaction rules, not a financial report or announcement of voting results. The document is lengthy (over 8,000 characters) and is a formal company policy document approved by the board and pending shareholder approval. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-10-10 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金管理制度" which translates to "Fundraising Capital Management System". It details the company's internal policies and procedures for managing and using raised funds, including storage, usage, supervision, and approval processes. The document references the company's board meetings and shareholder approvals but does not contain financial statements or results. It is a regulatory announcement about the management system for raised funds rather than a financial report or earnings release. The document length is over 7000 characters, indicating it is a substantive policy document rather than a brief announcement. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to fundraising and capital management policies.
2023-10-10 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the company's internal policies, principles, approval procedures, management, disclosure obligations, and responsibilities related to providing external guarantees. It includes references to board and shareholder meetings approving the system, but it is not a financial report, earnings release, or regulatory filing per se. It is a governance-related document outlining internal rules and procedures for managing external guarantees, which fits the Governance Information (CGR) category. The document length is 6567 characters, which is substantive and contains detailed policy content rather than a brief announcement or certification. Therefore, the best classification is Governance Information (CGR).
2023-10-10 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled as a "Profit Distribution Management System" of Jiangxi Xinganjiang Pharmaceutical Co., Ltd., detailing the company's policies and procedures for profit distribution, including dividend policies, decision-making processes, and supervisory mechanisms. It includes detailed internal governance rules about profit distribution, dividend forms, and shareholder rights. There is no financial data or financial statements presented, nor is it an announcement of a report publication. The document is a governance-related policy document issued by the board and intended for shareholders and regulatory compliance. It does not fit into financial reports like Annual Report (10-K) or Interim Report (IR), nor is it a voting result or dividend announcement. It aligns best with Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2023-10-10 Chinese
关于拟修订《公司章程》公告
Governance Information Classification · 95% confidence The document is an announcement regarding proposed amendments to the company's Articles of Association (公司章程). It details specific changes to governance rules, board structure, and procedures, referencing regulatory updates from the China Securities Regulatory Commission and Beijing Stock Exchange rules. The document is a formal notice from the company's board about these proposed changes, intended for shareholder consideration and regulatory filing. It does not contain financial statements, audit results, or detailed financial performance data. It is not a full report but an announcement of governance-related changes. Therefore, it fits best under the category of Governance Information (CGR). The document length (8093 characters) and content support this classification with high confidence.
2023-10-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.